Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC)
暂无分享，去创建一个
A. Dingemans | S. Ou | F. Barlesi | P. N. Morcos | B. Hughes | H. Léna | D-W. Kim | B. Balas | J. Ahn | L. Petris | A. Zeaiter | W. Bordogna | J.C. Yang | S. Golding | D. Kim